Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era

BACKGROUND: Pre-exposure prophylaxis for COVID-19 with tixagevimab/cilgavimab (T/C) received Emergency Use Authorization (EUA) based on results of a clinical trial conducted prior to the emergence of the Omicron variant. The clinical effectiveness of T/C has not been well described in the Omicron er...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Benjamin, Haste, Nina, Binkin, Nancy, Law, Nancy, Horton, Lucy E., Yam, Nancy, Chen, Victor, Abeles, Shira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138227/
https://www.ncbi.nlm.nih.gov/pubmed/37104498
http://dx.doi.org/10.1371/journal.pone.0275356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138227/
https://www.ncbi.nlm.nih.gov/pubmed/37104498
http://dx.doi.org/10.1371/journal.pone.0275356

Ejemplares similares